Endocrine Abstracts (2017) 50 OC2.2 | DOI: 10.1530/endoabs.50.OC2.2

Combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: A multi-centre, double-masked, factorial randomised controlled trial

Peter Taylor1, Rathie Rajendram2, Jimmy Uddin2, Richard Lee2 & Colin Dayan1


1Cardiff University, Cardiff, UK; 2Moorfields Eye Hospital, London, UK.


On behalf of the Combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) Investigators

Background: Thyroid eye disease is an inflammatory orbital condition which causes visual dysfunction and psychological morbidity. Current evidence is conflicting on the benefit of radiotherapy and antiproliferative immunosuppression in addition to systemic corticosteroid treatment. In particular, little is known about clinical outcomes more than 24 weeks after initiating these interventions.

Methods: CIRTED investigated the efficacy of orbital radiotherapy (RT) and azathioprine (AZA) vs placebo in combination with a standard 24-week tapering course of oral prednisolone in patients with active TED in a 2:2 factorial design. A composite outcome measure of treatment success was used with a primary end-point at 48 weeks.

Results: 126 subjects were randomized and primary outcome data were available in 103 (82%). Sixty-six (52%) withdrew from their treatment allocation beyond the period of radiotherapy/sham-radiotherapy but before the primary end point (61% in AZA, 40% in RT). Withdrawal due to abnormal blood tests or side-effects was more frequent with AZA (OR(adj) =5.90 (95%CI 2.06, 16.9) P=0.001. In an intention-to-treat analysis, the adjusted odds ratio for improvement was 2.54 (95%CI 0.98, 6.60, P=0.06) for AZA and 0.93 (95%CI 0.38, 2.26) P=0.87 for RT. For those completing therapy improvement was more frequent on AZA (OR(adj) =7.01 (95%CI 1.70, 28.8) P=0.007) than RT (OR(adj) =1.49 (95%CI 0.45, 4.9) P=0.50).

Interpretation: In patients receiving a 24-week course of oral prednisolone, no additional treatment benefit was seen with RT. Completion rates of AZA treatment were low, however those completing treatment derived substantial benefit at 48 weeks.

Article tools

My recent searches

No recent searches.